Genome-wide Analysis of MicroRNA and MRNA Expression Signatures in Cancer

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2015 Aug 25

PMID 26299954

Citations 34

Authors

Ming-Hui Li

Sheng-bo Fu

Hua-Sheng Xiao

Affiliations

Soon will be listed here.

Abstract

Cancer is an extremely diverse and complex disease that results from various genetic and epigenetic changes such as DNA copy-number variations, mutations, and aberrant mRNA and/or protein expression caused by abnormal transcriptional regulation. The expression profiles of certain microRNAs (miRNAs) and messenger RNAs (mRNAs) are closely related to cancer progression stages. In the past few decades, DNA microarray and next-generation sequencing techniques have been widely applied to identify miRNA and mRNA signatures for cancers on a genome-wide scale and have provided meaningful insights into cancer diagnosis, prognosis and personalized medicine. In this review, we summarize the progress in genome-wide analysis of miRNAs and mRNAs as cancer biomarkers, highlighting their diagnostic and prognostic roles.

Citing Articles

Construction and Validation of a Prognostic Model Based on Pyroptosis-related Genes in Bladder Cancer.

Shen C, Han C, Li Z, Yan Y, Li C, Chen H Comb Chem High Throughput Screen. 2023; 27(16):2335-2349.

PMID: 37849225 DOI: 10.2174/0113862073256363230929200157.

The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application.

Munoz J, Perez-Moreno P, Perez Y, Calaf G Diagnostics (Basel). 2023; 13(19).

PMID: 37835815 PMC: 10572677. DOI: 10.3390/diagnostics13193072.

Six potential biomarkers for bladder cancer: key proteins in cell-cycle division and apoptosis pathways.

Inal Gultekin G, Timirci Kahraman O, Isbilen M, Durmus S, Cakir T, Yaylim I J Egypt Natl Canc Inst. 2022; 34(1):54.

PMID: 36529823 PMC: 9760318. DOI: 10.1186/s43046-022-00153-0.

MicroRNA signature of small-cell lung cancer after treatment failure: impact on oncogenic targets by miR-30a-3p control.

Tanigawa K, Misono S, Mizuno K, Asai S, Suetsugu T, Uchida A Mol Oncol. 2022; 17(2):328-343.

PMID: 36345848 PMC: 9892828. DOI: 10.1002/1878-0261.13339.

MicroRNAs and Their Big Therapeutic Impacts: Delivery Strategies for Cancer Intervention.

Holjencin C, Jakymiw A Cells. 2022; 11(15).

PMID: 35954176 PMC: 9367537. DOI: 10.3390/cells11152332.

References

Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J . miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer. 2009; 19(4):641-7. DOI: 10.1111/IGC.0b013e3181a48cf9. View

Huang T, Yang J, Cai Y . Novel candidate key drivers in the integrative network of genes, microRNAs, methylations, and copy number variations in squamous cell lung carcinoma. Biomed Res Int. 2015; 2015:358125. PMC: 4352729. DOI: 10.1155/2015/358125. View

Berkel H, Turbat-Herrera E, Shi R, De Benedetti A . Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev. 2001; 10(6):663-6. View

Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N . Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011; 32(3):583-8. DOI: 10.1007/s13277-011-0154-9. View

Boise L, Gonzalez-Garcia M, Postema C, Ding L, LINDSTEN T, Turka L . bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74(4):597-608. DOI: 10.1016/0092-8674(93)90508-n. View

Dai X, Chen A, Bai Z . Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. Sci Rep. 2014; 4:6566. PMC: 4206873. DOI: 10.1038/srep06566. View

Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J . Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol. 2011; 22(10):2257-66. DOI: 10.1093/annonc/mdq758. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Pradervand S, Weber J, Thomas J, Bueno M, Wirapati P, Lefort K . Impact of normalization on miRNA microarray expression profiling. RNA. 2009; 15(3):493-501. PMC: 2657010. DOI: 10.1261/rna.1295509. View

10.

Xiao W, Tran B, Staudt L, Schmitz R . High-throughput RNA sequencing in B-cell lymphomas. Methods Mol Biol. 2013; 971:295-312. PMC: 7605114. DOI: 10.1007/978-1-62703-269-8_17. View

11.

Azim Jr H, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M . Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol. 2013; 24(3):647-54. PMC: 6267878. DOI: 10.1093/annonc/mds645. View

12.

Wang S, Wang L, Bayaxi N, Li J, Verhaegh W, Janevski A . A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut. 2012; 62(2):280-9. DOI: 10.1136/gutjnl-2011-301554. View

13.

Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo J . Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer. 2012; 12:260. PMC: 3571914. DOI: 10.1186/1471-2407-12-260. View

14.

Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N . MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-36. PMC: 2614237. DOI: 10.1001/jama.299.4.425. View

15.

Heneghan H, Miller N, Kelly R, Newell J, Kerin M . Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010; 15(7):673-82. PMC: 3228012. DOI: 10.1634/theoncologist.2010-0103. View

16.

DeFatta R, Turbat-Herrera E, Li B, Anderson W, De Benedetti A . Elevated expression of eIF4E in confined early breast cancer lesions: possible role of hypoxia. Int J Cancer. 1999; 80(4):516-22. DOI: 10.1002/(sici)1097-0215(19990209)80:4<516::aid-ijc6>3.0.co;2-7. View

17.

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

18.

Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H . Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64(11):3753-6. DOI: 10.1158/0008-5472.CAN-04-0637. View

19.

Chan J, Kiet T, Blansit K, Ramasubbaiah R, Hilton J, Kapp D . MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. Gynecol Oncol. 2014; 133(3):568-74. DOI: 10.1016/j.ygyno.2014.03.564. View

20.

Brodtkorb M, Lingjaerde O, Huse K, Troen G, Hystad M, Hilden V . Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood. 2013; 123(7):1051-4. DOI: 10.1182/blood-2013-07-512392. View